vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $37.2M, roughly 1.4× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -5.1%, a 1.4% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -14.2%). READING INTERNATIONAL INC produced more free cash flow last quarter ($4.1M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 5.6%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
GYRE vs RDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $50.3M |
| Net Profit | $-1.4M | $-2.6M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | -1.9% |
| Net Margin | -3.7% | -5.1% |
| Revenue YoY | 33.4% | -14.2% |
| Net Profit YoY | -340.1% | -14.5% |
| EPS (diluted) | $-0.01 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $50.3M | ||
| Q3 25 | $30.6M | $52.2M | ||
| Q2 25 | $26.8M | $60.4M | ||
| Q1 25 | $22.1M | $40.2M | ||
| Q4 24 | $27.9M | $58.6M | ||
| Q3 24 | $25.5M | $60.1M | ||
| Q2 24 | $25.2M | $46.8M | ||
| Q1 24 | $27.2M | $45.1M |
| Q4 25 | $-1.4M | $-2.6M | ||
| Q3 25 | $5.9M | $-4.2M | ||
| Q2 25 | $1.6M | $-2.7M | ||
| Q1 25 | $3.7M | $-4.8M | ||
| Q4 24 | $569.0K | $-2.2M | ||
| Q3 24 | $2.9M | $-7.0M | ||
| Q2 24 | $4.5M | $-12.8M | ||
| Q1 24 | $9.9M | $-13.2M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | -1.9% | ||
| Q3 25 | 22.7% | -0.6% | ||
| Q2 25 | 8.1% | 4.8% | ||
| Q1 25 | 10.3% | -17.2% | ||
| Q4 24 | 2.4% | 2.6% | ||
| Q3 24 | 16.6% | -0.6% | ||
| Q2 24 | 12.7% | -16.4% | ||
| Q1 24 | 29.7% | -16.7% |
| Q4 25 | -3.7% | -5.1% | ||
| Q3 25 | 19.4% | -8.0% | ||
| Q2 25 | 5.9% | -4.4% | ||
| Q1 25 | 16.9% | -11.8% | ||
| Q4 24 | 2.0% | -3.8% | ||
| Q3 24 | 11.2% | -11.7% | ||
| Q2 24 | 18.0% | -27.4% | ||
| Q1 24 | 36.6% | -29.4% |
| Q4 25 | $-0.01 | $-0.11 | ||
| Q3 25 | $0.03 | $-0.18 | ||
| Q2 25 | $0.00 | $-0.12 | ||
| Q1 25 | $0.00 | $-0.21 | ||
| Q4 24 | $0.00 | $-0.11 | ||
| Q3 24 | $0.01 | $-0.31 | ||
| Q2 24 | $0.01 | $-0.57 | ||
| Q1 24 | $0.03 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $106.0M | $-18.2M |
| Total Assets | $166.1M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $10.5M | ||
| Q3 25 | $60.0M | $8.1M | ||
| Q2 25 | $54.4M | $9.1M | ||
| Q1 25 | $29.9M | $5.9M | ||
| Q4 24 | $26.7M | $12.4M | ||
| Q3 24 | $25.1M | $10.1M | ||
| Q2 24 | $25.1M | $9.3M | ||
| Q1 24 | $37.4M | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $106.0M | $-18.2M | ||
| Q3 25 | $101.9M | $-12.1M | ||
| Q2 25 | $92.0M | $-7.7M | ||
| Q1 25 | $68.1M | $-8.1M | ||
| Q4 24 | $63.3M | $-4.4M | ||
| Q3 24 | $63.2M | $1.6M | ||
| Q2 24 | $60.4M | $6.5M | ||
| Q1 24 | $56.6M | $18.0M |
| Q4 25 | $166.1M | $434.9M | ||
| Q3 25 | $159.4M | $435.2M | ||
| Q2 25 | $152.6M | $438.1M | ||
| Q1 25 | $129.8M | $441.0M | ||
| Q4 24 | $125.4M | $471.0M | ||
| Q3 24 | $125.2M | $495.7M | ||
| Q2 24 | $120.9M | $494.9M | ||
| Q1 24 | $122.0M | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $4.3M |
| Free Cash FlowOCF − Capex | $-5.8M | $4.1M |
| FCF MarginFCF / Revenue | -15.5% | 8.2% |
| Capex IntensityCapex / Revenue | 0.4% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $4.3M | ||
| Q3 25 | $4.7M | $295.0K | ||
| Q2 25 | $2.1M | $1.6M | ||
| Q1 25 | $-129.0K | $-7.7M | ||
| Q4 24 | $-2.8M | $8.0M | ||
| Q3 24 | $1.7M | $1.3M | ||
| Q2 24 | $-5.5M | $-10.4M | ||
| Q1 24 | $2.9M | $-2.8M |
| Q4 25 | $-5.8M | $4.1M | ||
| Q3 25 | $4.0M | $-246.0K | ||
| Q2 25 | $1.8M | $1.2M | ||
| Q1 25 | $-251.0K | $-8.0M | ||
| Q4 24 | $-2.8M | $7.0M | ||
| Q3 24 | $1.0M | $-1.1M | ||
| Q2 24 | $-6.9M | $-10.6M | ||
| Q1 24 | $2.7M | $-4.7M |
| Q4 25 | -15.5% | 8.2% | ||
| Q3 25 | 13.1% | -0.5% | ||
| Q2 25 | 6.8% | 1.9% | ||
| Q1 25 | -1.1% | -19.8% | ||
| Q4 24 | -10.1% | 12.0% | ||
| Q3 24 | 4.1% | -1.8% | ||
| Q2 24 | -27.5% | -22.7% | ||
| Q1 24 | 9.8% | -10.4% |
| Q4 25 | 0.4% | 0.3% | ||
| Q3 25 | 2.2% | 1.0% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 2.7% | 4.0% | ||
| Q2 24 | 5.8% | 0.5% | ||
| Q1 24 | 0.9% | 4.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
